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Propagation of errors calculation 
The propagation of error for koff was calculated as follows: 
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MALDI-TOF mass spectrometry 
MALDI-TOF MS was carried out on a Shimadzu Axima-CFRTM plus MALDI-TOF mass spectrometer 
operating in the linear mode in the 500 to 14,000 m/z range. For the characterization of the mPEG-OH and 
mPEG-acrylates, saturated dithranol matrix in dichloromethane (DCM) with 30 wt % sodium trifluoroacetate 
(NaTFA), was used. NaTFA-matrix solution was mixed in a 1 : 1 volume ratio with the mPEG-OH or mPEG-
acrylate (1 mg·mL-1) dissolved in DCM from which 1 L was applied to the plate. For analysis of the peptides 
and the mPEG-peptide conjugates, a 10 mg·mL-1 matrix solution of α-cyanohydroxycinnamic acid matrix 
dissolved in THF was used. The matrix solution was mixed in a 1 : 1 volume ratio with the mPEG-peptide 
conjugates dissolved in MilliQ water (1 mg/mL). The samples were placed on the MALDI-TOF plate and 
allowed to dry. Calibration was achieved using several references: Angiotensin II ([M+H+] = 1045.54), 
adrenocorticotropic hormone18-39 (ACTH18-39) peptide fragment ([M+H
+] = 2464.20) and bovine insulin 
([M+H+] = 5729.61). Measurements were performed with a laser power of 45-65 (max. laser power: 180).  
 
Gel permeation chromatography (GPC) 
All GPC analyses were performed on a Viscotek triple detector array Model 300 equipped with a 
MetaChem degasser, Viscotek VE 1121 GPC solvent pump, VE 5200 GPC autosampler and Shodex-OH pak 
804 and 805 columns. GPC of PEG750, PEG2000, mid-functionalized poly(ethylene glycol)-co-(glycerol) 
and hyperbranched-poly(glycerol) was performed at 25 oC in 9 : 1 volume ratio of 0.1 M potassium phosphate 
buffer pH 6.6 and methanol, respectively. The chromatograms were analyzed according to a conventional 
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calibration against PEG standards. Table S1 presents the molecular weight characteristics obtained via GPC. 
GPC elugrams are shown in Figure S4. 
 
NMR spectrometry 
All NMR spectra were recorded using either a Bruker AC 300 (300 MHz) or a Bruker AMX 400 (400 
MHz) instrument. The spectra were referenced internally to the residual proton signals of the deuterated 
solvent (DMSO-d6 or CDCl3). 
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Table S1. Molecular weight characteristics of the acrylate- and maleimide- end group modified polymers used 













PEG-750-acrylate, 1 790 720 700 1.03 
PEG-2000-acrylate, 2 1960 1900 1800 1.04 
mid-P(EG-co-G)-maleimide, 3 1780 2000 1700 1.16 
hbPG-maleimide, 4 2050 3000 2200 1.36 
a Number-average molecular weight determined by comparison of the acrylate or maleimide end-groups 
versus the polymer backbone in 1H-NMR. 
b Molecular weight of the acrylate- and maleimide modified polymers determined by gel permeation 
chromatography against PEG standards using an eluent consisting of 90 vol. % 0.1 M potassium phosphate 































































































































































Figure S1. 1H-NMR spectrum of maleimido-modified hyperbranched-poly(glycerol) 4. 
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Figure S2. 1H-NMR spectrum of maleimido-modified mid-functional P(EG-co-G) copolymer, 3. 
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Figure S3. 1H-NMR spectra of (a) PEG750-acrylate (1) and (b) PEG2000-acrylate 2. 
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Figure S4. Gel permeation chromatograms of mPEG750 acrylate (1), mPEG2000 acrylate (2), mid-P(EG-co-
G)-maleimide (3) and hyperbranched PG (4). The chromatograms are cut-off at 19.6 min due to the presence 
the solvent peak which produces a large negative signal. 
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Figure S5. Analytical reverse phase HPLC chromatograms of the (a) unmodified C41 peptide, (b) N-terminal 
cysteine modified peptide, (c) S15C peptide, (d) C-terminal cysteine modified peptide and (e) S20C peptide. 
The insets depict the MALDI-TOF mass spectra obtained for each sample. 
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Figure S6. Analytical reverse phase HPLC chromatograms of (a) N-terminal-hbPG, (b) N-terminal-mid-
functional P(EG-co-G), (c) N-terminal-PEG750 and (d) N-terminal-PEG2000 conjugates. The insets depict 
the MALDI-TOF mass spectra obtained for each sample. 
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Figure S7. Analytical reverse phase HPLC chromatograms of (a) S15C-hbPG, (b) S15C-mid-functional 
P(EG-co-G), (c) S15C-PEG750 and (d) S15C-PEG2000 conjugates. The insets depict the MALDI-TOF mass 
spectra obtained for each sample. 
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Figure S8. Analytical reverse phase HPLC chromatograms of (a) C-terminal-hbPG, (b) C-terminal-mid-
functional P(EG-co-G), (c) C-terminal-PEG750 (d) and C-terminal-PEG2000 conjugates. The insets depict the 




Figure S9. HIV-1HXB2 infectivity inhibition of the PEGylated S20C conjugates (a) and the S20C – mid-
functional P(EG-co-G) and S20C – hyperbranched polyglycerol (b) with HOS CCR5 cells. The error bars 
indicate standard error of mean (SEM) of 3 or more independent experiments, each performed in duplicate. 
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Figure S10. Illustration of the kinetics exclusion assay (KinExA) using fluorescein modified 5-Helix (5H-f) 
and C37 modified azlactone beads. (a) Through pre-equilibration of the query peptide or peptide – polymer 
conjugate with the 500 pM fluorescein modified 5-Helix (5H-f) and subsequent injection of a titration series 
of these peptide – 5H-f mixtures over C37 modified azlactone beads, the fraction free 5H-f can be derived. (b) 
Example of the KinExA read out obtained with a titration series of C-terminal PEG2000 with 500 pM 5H-f 
with I and W indicating injection and buffer wash, respectively. (c) Example of the corresponding KinExA 
binding curve obtained from the titration of C-terminal PEG2000 conjugate with 500 pM 5H-f over C37 
modified azlactone beads. The titration data is fitted using a bimolecular equilibrium binding model (red line). 
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Figure S12. Comparison of the kinetic rates of association, kon of HR2-derived C41 and peptide – polymer 
conjugates with fluorescein modified 5-Helix. The error bars indicate standard error of mean (SEM) of 3 or 




Figure S13. Comparison of the kinetic rates of dissociation, koff of HR2-derived C41 and peptide – polymer 
conjugates with fluorescein modified 5-Helix. The error bars indicate standard error of mean (SEM) of 3 or 
more independent experiments, each performed in duplicate. 
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Figure S15. Affinity of (a) C-terminal-PEG750, (b) C-terminal-PEG2000, (c) C-terminal-mid-functional 




Figure S16. Affinity of (a) S15C-PEG750, (b) S15C-PEG2000, (c) S15C-mid-functional P(EG-co-G), (d) 
S15C-hbPG towards fluorescein modified 5-Helix (5H-f). 
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Figure S17. Affinity of (a) N-terminal-PEG750, (b) N-terminal-PEG2000, (c) N-terminal-mid-functional 
P(EG-co-G), (d) N-terminal-hbPG towards fluorescein modified 5-Helix (5H-f). 
 
